Subscribe to NRx Newsletter
Hope Therapeutics
Hope Therapeutics, an NRx Pharma daughter company, is developing NRX-100 (IV Ketamine) for treatment of Acute Suicidality and Depression. View our recent keynote address at the Sachs Neuroscience Forum on Jan 7, 2024 to learn more about how we’re bringing hope to 3.5 million lives in the United States. A copy of the keynote presentation is available below.

For further information please contact: 

Matthew Duffy, Chief Business Officer,
Jonathan C. Javitt, M.D., M.P.H. Chairman and Chief Scientist,